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Although vascular calcification (VC) is prevalent in Type 2 diabetes mellitus (T2DM), underly-
ing mechanisms remain unclear. Neither is it known whether T2DM confers calcific potential
(CP) on serum, enabling it to induce VC outside the disease milieu. We, therefore, investig-
ated the CP of serum from controls and subjects with T2DM with and without in vivo VC.
Samples from 20 healthy controls and 44 age- and sex-matched patients with T2DM with
modification of diet in renal disease estimated glomerular filtration rate (MDRD-4 eGFR) >
60 ml·min− 1 were analysed for CP using rat aortic smooth muscle cells in vitro. CT scans
of femoral arteries identified individuals with in vivo calcification. Serum from subjects with
T2DM revealed significantly greater CP than controls. This was further enhanced in the pres-
ence of in vivo VC. Addition of β-glycerophosphate (β-GP) plus CaCl2 increased the CP of
T2DM serum but not of controls. Along with age, CP was an independent predictor of the
presence of VC. In receiver operator curve (ROC) analysis, CP was a significant predictor of
femoral arterial VC (C-statistic 0.70: P=0.009). The distribution of CP was bimodal around
a cutoff of 100 nmoles of Ca2+ protein mg− 1, with a higher proportion of Type 2 diabetes
subjects with in vivo calcification (T2DM+ ) sera above the cutoff value. This group also
showed elevated levels of osteoprotegerin (OPG) and matrix Gla protein (MGP). Diabetes
confers CP on the serum which is enhanced by the presence of in vivo VC. The CP acquired
may be dependent on levels of OPG and MGP. These findings may be clinically relevant for
early identification of individuals at risk of VC and for informing therapeutic strategies.
Introduction
The major cause of mortality in subjects with Type 2 diabetes mellitus (T2DM) is cardiovascular disease.
Vasculopathy is an early and seemingly inevitable feature of T2DM. It is linked to enhanced oxidative stress
and endothelial cell dysfunction which act as an initial trigger for the progression of atherosclerosis and
vascular calcification (VC) [1]. The latter is widely acknowledged to be a biologically orchestrated process
in which vascular aortic smooth muscle cells (VASMCs) differentiate into an osteo/chondrogenic phen-
otype [2]. This phenotypic switch has been implicated in the pathogenesis of various diseases, including
diabetes, with detrimental clinical consequences. Although patients with T2DM have significantly more
VC compared with the general population, much remains unknown of the pathophysiology of VC in this
setting. The underlying mechanisms which mediate this process have not been fully defined [3,4]. It is
also not clear whether circulating factors generated prior to, or as a consequence of disease manifestation,
initiate or contribute to the progression of calcification within the vessel wall.
Clinically, VC is assessed by non-invasive quantification of calcification using X-ray, computed tomo-
graphy (CT) scanning or MRI. However, scanning not only requires expensive instrumentation but also
detects VC when already established [5–7]. Currently, we have no means of predicting an individual’s risk
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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of developing VC.We have previously demonstrated that serum from individuals with chronic kidney disease (CKD)
induces calcification of VASMCs in vitro. This effect, which we have referred to as the calcific potential (CP) of
serum, increases with advancing CKD [8] but more importantly identifies individuals at risk of calcification under
conditions which favour this process. To further validate our model and demonstrate whether CP is selective to
CKD or a common characteristic of disease states associated with VC, we have extended our studies by assessing the
capacity of serum from patients with T2DM to cause calcification. These studies were aimed at determining whether
serum from patients with T2DM has a greater in vitro CP than normal age- and sex-matched controls and whether
this correlates with in vivo calcification assessed by CT scanning. Such a phenomenon may have significant clinical
implications. The findings could be exploited to develop diagnostic and prognostic tests to determine an individual’s
risk of developing VC and inform therapeutic strategies.
Research design and methods
Ethical approval
Ethical approval was obtained from the Hertfordshire Research Ethics Committee (Protocol number: 10/H0311/28).
The procedures followed were in accordance with the ethical standards of the responsible committee on human ex-
perimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study
subjects gave written informed consent prior to recruitment.
Patient selection
Forty-four age-matched T2DM subjects and 20 healthy controls were studied. All were Caucasians and had preserved
renal function with modification of diet in renal disease estimated glomerular filtration rate (MDRD-4 eGFR) >
60 ml·min− 1. All the T2DM subjects were on oral hypoglycaemic drugs such as sulphonylureas and/or metformin
(30 patients) and pioglitazone or rosiglitazone (10 patients). Four patients were additionally on insulin.
Determination of in vivo vascular calciﬁcation
A CT scan of 5 cm segments of the femoral artery was carried out in both the groups as previously described to
determine in vivo calcification [1,9]. The degree of VC was expressed as the Agatston score for each artery, and the
greater of the two was used in subsequent analysis. Four groups were defined depending on the presence or absence
of VC and designated as control with in vivo calcification (C+ ) or control without in vivo calcification (C− ), and
subjects with diabetes with in vivo calcification (T2DM+ ) and without in vivo calcification (T2DM− ).
Biochemical analyses of blood samples
Blood samples were taken from all subjects and routine analyses performed which included full blood count, blood
urea, glucose, glycosylated haemoglobin (HbA1c), serum creatinine, albumin, calcium, phosphate and lipid profiles.
Other samples for specified analysis including parathyroid hormone (PTH), osteoprotegerin (OPG), receptor activ-
ator of nuclear factor kappa B ligand (RANKL) andmatrix Gla protein (MGP) were isolated in Z serum sep clot activ-
ator VACUTTE R© by centrifugation at 2000 g for 15 min at 4 ◦C and stored at − 80 ◦C until analysis. Serum levels of
PTH were measured using the Beckman Access R© 2 immunoassay system (Beckman Coulter, High Wycombe, U.K.).
Assays for OPG and RANKL were performed using the automated enzyme-linked immunosorbent assay (ELISA)
analyzer, Triturus R© (Grifols, Cambridge, U.K.).MGPwasmeasured using the BIOMEDICAGRUPEEKit (BI-20062).
All analyses were performed in duplicate.
Induction and quantiﬁcation of calciﬁcation
Rat VASMCs were isolated and cultured from aortic strips as described previously [10]. All experiments were car-
ried out using cells at passage 3 to 5 and at a confluence of 60 to 70% in 96-well plates. The CP of sera samples
was determined by incubating cells with 10% serum in standard Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with penicillin (100 U·ml− 1) and streptomycin (100μg·ml− 1). In parallel studies, CaCl2 (7 mM) and
β-glycerophosphate (β-GP; 7 mM) (calcification buffer; CB) in combination with 10% serum were used. Cells were
lysed after 5 days of incubation using lysis buffer (10 mM Tris/HCl (pH 7.4) and 10% (w/v) SDS. Calcification was
assessed using the DICA-500 Ca2+ assay kit [8] and total cell protein was determined using the bicinchoninic acid
(BCA) assay as described previously [10]. Once determined, calcium levels in lysates were normalized with total cell
protein per well and the data presented as nmoles of Ca2+ mg of protein− 1.
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Figure 1. Agatston calciﬁcation scores (panel A) and in vitro CP of serum (panel B) from control and diabetes groups
The data represent the medians and IQR. Figure (B) represents the data from three individual experiments with five replicates in each.
Materials
Cell culture and other general biochemical reagents including CaCl2 and β-GP were purchased from Sigma–Aldrich
(London, U.K.). Penicillin and streptomycin were from Fisher Scientific (Loughborough, U.K.) and foetal bovine
serum (FBS) from Gibco (Scotland, U.K.). The BCA protein quantification kit was from Thermo Scientific (Hemel
Hempstead, U.K.) and the DICA-500 Ca2+ assay kit was from Universal Biologicals (Cambridge, U.K.). Reagents for
the assay of OPG, RANKL and MGP were obtained from Oxford Biosystems (Oxford, U.K.).
Statistical analysis
Statistical Package for Social Sciences (SPSS) version 17 (SPSS Inc., Chicago, U.S.A.) was used for data analysis and
presented either as means +− S.D. or as median (interquartile range, IQR) as appropriate. For continuous variables,
the significance of differences between two groups was determined by independent t-test (for normally distributed
data) and the Mann–Whitney U tests or Wilcoxon test (for non-normally distributed data). Either one-way ANOVA
or the Kruskal–Wallis test was employed as appropriate to assess differences between multiple groups. Categorical
data were analysed using χ 2 test. Correlations were computed either as Pearson’s or Spearman’s for parametric and
non-parametric distributed data respectively. Logistic regression analysis and receiver operator curve (ROC) analysis
were used to examine the relationships of CP and the presence of VC.
Results
Comparison of biochemical variables and calciﬁcation in diabetes and
control groups
There was no difference between the diabetes and control groups with respect to mean age or gender ratios (Table 1).
Both groups had preserved renal function with eGFR more than 60 ml·min− 1·1.73 m− 2, though urinary albu-
min/creatinine ratio (ACR) was higher in patients with diabetes and serum albumin was slightly lower. There were
significant differences in lipid profiles which were generally better in patients with diabetes, presumably because they
were on lipid lowering therapy. Diastolic BP was also lower in diabetes patients. Serum PTH, OPG and RANKL levels
did not differ between the groups though MGP levels were higher in those with diabetes.
Agatston score was higher in patients with diabetes (Table 1 and Figure 1; panel A). The score correlated with
age (rho= 0.611, p < 0.001), diastolic BP (rho= − 0.402, p = 0.002), pulse pressure (rho= 0.547, p < 0.001), serum
creatinine (rho= 0.303, p < 0.01), urinary ACR (rho= 0.315, p < 0.01) and serum OPG (rho= 0.439, p < 0.001).
There were no correlations with serum calcium, phosphate, PTH, RANKL and MGP.
Serum from subjects with diabetes had a higher median CP (73 (IQR 76)) than controls (37 (IQR 41): p < 0.001)
(Table 1 and Figure 1; panel B). The CP correlated positively with serum OPG (rho= 0.360, p = 0.004), MGP levels
(rho= 0.313, p = 0.014) and pulse pressure (rho= 0.327, p = 0.011), but not with age, serum creatinine, eGFR, serum
calcium, phosphate, albumin or PTH.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC-BY).
993
Clinical Science (2017) 131 994–1000
DOI: 10.1042/CS20160882
Table 1 Comparison of biochemical variables and of calciﬁcation in diabetes and control groups
Normally distributed parameters are presented as means +− S.D.; non-normally distributed parameters are presented as medians
(IQR). DBP, diastolic blood pressure; eGFR (ml·min−1·1.73m−2), estimated glomerular filtration rate calculated using modification
of diet in renal disease (MDRD-4) formula; HDL, high-density lipoprotein; NS, non-significant; SBP, systolic blood pressure.
Variables Controls Diabetes P-value
Number 20 44 –
Age (yrs) 63+−6 64+−12 NS
Gender (M:F) 9/11 21/23 NS
SBP (mmHg) 149+−24 149+−19 NS
DBP (mmHg) 87+−9 80+−11 =0.025
Pulse Pressure (mmHg) 55(24) 69(22) =0.07
Creatinine (μmol/l) 72+−17 79+−29 NS
eGFR (MDRD 4) 93+−23 91+−23 NS
ACR (mg/mmol) 0(3.2) 4.3(26.5) <0.001
Calcium (mmol/l) 2.49+−0.13 2.46+−0.10 NS
Phosphate (mmol/l) 1.02+−0.15 1.05+−0.15 NS
PTH (pmol/l) 2.9(2.4) 3.4(2.9) NS
Albumin (g/l) 45.4+−2.5 43.6+−3.1 =0.02
CRP > 5 mg/l (%) 15 10 NS
Cholesterol (mmol/l) 5.8+−1.0 3.9+−0.9 <0.001
HDL (mmol/l) 1.5+−0.3 1.3+−0.3 =0.008
Cholesterol/HDL 3.9+−0.8 3.1+−0.7 <0.001
OPG (pmol/l) 4.0+−1.5 4.3+−1.4 NS
RANKL (pmol/l) 0(0.06) 0(0.07) NS
MGP (ng/ml) 15.9+−1.4 17.7+−3.4 = 0.020
HbA1c (g/dL) 5.7+−0.5 7.8+−1.4 <0.001
DCCT (%; mmol/mol) 39+−5 62+−15
Calciﬁcation Potential 37(41) 73(76) <0.001
Agatston Score 0(173) 144(875) =0.025
Comparison of biochemical variables and calciﬁcation in diabetes and
control groups stratiﬁed for the presence of in vivo calciﬁcation
The control and diabetes groups were further categorized on the basis of presence or absence of femoral calcification
and divided into four groups: Group 1 (9 controls without in vivo calcification; C− ), Group 2 (11 Controls with
in vivo calcification; C+ ), Group 3 (17 DM without in vivo calcification; T2DM− ) and Group 4 (27 DM with
in vivo calcification; T2DM+ ).
Subjects with in vivo VC were older than their non-calcified counterparts in both the control and diabetes groups
(Table 2). Diastolic blood pressure was lower in T2DM+ group compared with the C+ group. Renal function was
not different between the groups, though urinary ACR was higher in those with diabetes and serum albumin levels
were lower in T2DM+ than in C+ . As previously mentioned, lipid profiles were generally better in those with
diabetes. Serum calcium, phosphate, serum PTH and RANKL did not differ between groups. Serum OPG levels,
however, were significantly higher in subjects with in vivo VC (either C+ or T2DM+ ) compared with subjects
without in vivoVC.Also, T2DM+ had significantly higher levels ofMGP thanC+ . Therewas no difference between
HbA1c levels in T2DM− and T2DM+ .
The CP of sera from patients with VC (74 (IQR 85)) was higher than that of sera from those without VC (57 (IQR
44): p = 0.009). The CP did not show statistically significant difference between C+ and C− but was significantly
higher for T2DM+ when compared with these two groups (p < 0.05; in both cases) and approached significance for
sera from T2DM− (P = 0.055) (Figure 2; panel A).
Effect of addition of calciﬁcation buffer
The addition of CB revealed marked differences between CP of controls and of sera from subjects with diabetes
(Figure 2; panel B). After the addition of CB, the CP was marginally enhanced in C− (P = 0.028) and C+
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Table 2 Comparison of biochemical variables and calciﬁcation in diabetes and control groups stratiﬁed for
the presence of in vivo calciﬁcation
Normally distributed parameters are presented as means +− S.D.; non-normally distributed parameters are presented as medians (IQR). NS,
non-significant.









P-value P-value P-value P-value
Number 9 11 17 27 NS NS NS NS
Age (yrs.) 60+−4 66+−7 56+−14 69+−8 =0.038 NS NS =0.002
Gender (M:F) 4/5 5/6 7/10 14/13 NS NS NS NS
SBP (mmHg) 140+−11 159+−29 146+−15 150+−21 =0.067 NS NS NS
DBP (mmHg) 87+−9 88+−10 84+−10 77+−12 NS NS 0.028 =0.066
Pulse Pressure (mm/Hg) 52+−11 72+−28 61+−15 73+−19 =0.065 NS NS =0.075
Creatinine (μmol/l) 67+−19 75+−15 76+−15 81+−26 NS NS NS NS
eGFR (MDRD 4) 98+−28 90+−20 99+−21 87+−23 NS NS NS NS
ACR (mg/mmol) 0(8.8) 0(2.1) 3.8(12.9) 8.0(42.1) NS =0.058 <0.001 NS
Calcium(mmol/l) 2.43+−0.12 2.53+−0.13 2.46+−0.11 2.46+−0.09 NS NS NS NS
Phosphate (mmol/l) 1.05+−0.17 0.99+−0.14 1.04+−0.14 1.05+−0.16 NS NS NS NS
PTH (pmol/l) 3.1(1.4) 5.1(2.0) 3.4(1.8) 3.4(2.5) 0.08 NS 0.061 NS
Albumin (g/l) 44.8+−2.8 45.8+−2.3 44.5+−2.1 43.1+−3.6 NS NS =0.027 NS
Cholesterol (mmol/l) 6.4+−0.9 5.4+−0.9 3.8+−0.9 3.9+−0.9 =0.025 <0.001 <0.001 NS
HDL (mmol/l) 1.6+−0.3 1.4+−0.2 1.3+−0.4 1.3+−0.3 NS =0.058 NS NS
Cholesterol/HDL 4.1+−1.0 3.8+−0.6 3.1+−0.8 3.1+−0.7 NS =0.014 =0.008 NS
OPG (pmol/l) 3.5+−1.4 4.5+−1.6 3.4+−1.1 4.8+−1.3 =0.013 NS NS =0.022
RANKL(pmol/l) 0(0.11) 0.0(0.02) 0.04(0.29) 0(0.03) NS NS NS NS
MGP (ng/ml) 16.4+−1.6 15.3+−1.2 17.7 +− 3.3 17.7+−3.5 =0.085 NS =0.036 NS
HbA1c(g/dL) 5.7+−0.7 5.7+−0.4 8.2+−1.5 7.6+−1.3
DCCT (%; mmol/mol) 39+−7 39+−5 66+−17 60+−14 NS <0.001 <0.001 NS
Calciﬁcation Potential 27(21) 52(65) 65(24) 83(82) NS =0.001 =0.027 =0.055
Agatston Score – 86(246) – 785(1423) <0.001
Figure 2. Effects of in vivo calciﬁcation on the in vitro CP of serum from control and diabetes groups
The data shown in panel A are with serum alone, in panel B are for serum with CaCl2 (7 mM) plus β-GP (7 mM) and in panel C combined
both (A) and (B). The data represent the medians and IQR from three individual experiments with five replicates in each.
(non-significant (NS), P = 0.115), but significantly increased by comparison in T2DM− (P<0.001) and in T2DM+
(P = 0.003; Figure 2; panel C), with that of the T2DM− being greater than in T2DM+ group.
Relationship of in vitro CP and in vivo VC
The correlation between CP and Agatston score across all samples was weak (rho= 0.209, P = 0.097). In logistic re-
gression analysis (Table 3), the independent determinants of the presence of femoral arterial VC were age and CP.
Themodel accounted for 45% of the variation (Nagelkerke’s R2 = 0.447). Adding other factors including the presence
of diabetes, serum creatinine, MDRD-4 eGFR, urinary ACR, serum C-reactive protein (CRP), calcium, phosphate,
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 3 Logistic regression analysis for determinants of the presence of femoral arterial
calciﬁcation
95% Conﬁdence interval for Exp(B)
B S.E. Wald P-value Exp(B) Lower Upper
Age (years) 0.125 0.039 10.091 0.001 1.133 1.049 1.224
Calciﬁcation potential 0.020 0.009 5.097 0.024 1.020 1.003 1.037
Constant − 8.725 2.551 11.700 0.001 0.000
Figure 3. Frequency distribution of serum CP
CP was plotted against the frequencies and divided further into two peaks, with peak 1 representing CP correlating with <100 nmoles Ca2+
protein mg−1 and peak 2 representing CP correlating with 100 nmoles Ca2+ protein mg−1. The inset shows numbers of subjects in the
two peaks.
PTH, RANKL, OPG and MGP did not improve the model significantly. In ROC analysis, CP was a significant pre-
dictor of the presence of femoral arterial VC (C-statistic 0.70: P = 0.009). A cutoff of 100 nmoles of Ca2+ protein
mg− 1 predicted the presence of VC with a sensitivity of 33% and a specificity of 92%.
Distribution of calciﬁc potential
A plot of the distribution of CP was bimodal, consisting of 48 subjects with CP <100 and 16 subjects with CP 
100 nmoles of Ca2+ protein mg− 1 (Figure 3). Of the 16 subjects with the higher CP, 11 were T2DM+ (69%), 3
T2DM− (19%) and 2 C+ (12%) but none were C− (P = 0.013 for T2DM+ compared with other groups com-
bined). Moreover, 81% of subjects with CP values above the cutoff had in vivo VC compared to 52% with lower
values.
Serum OPG was significantly higher in sera above the cutoff (5.2+− 1.3 compared with 3.9+− 1.3 pmol·l− 1:
P = 0.005). Similarly, differences in MGP levels approached significance (18.3+− 3.5 compared with
16.7+− 2.8 ng·ml− 1: P = 0.078). In logistic regression analysis, both MGP and OPG were predictive of mem-
bership of the group above the cutoff (Nagelkerke’s R2 = 0.269: P < 0.001). Adding age, eGFR, serum levels of
calcium, phosphate, CRP, the presence of diabetes and the presence of VC did not improve this model.
Discussion
VC, a process of dynamic and pathological biomineralization of the vascular wall, involves VASMCswhichmay either
calcify in the medial layer or migrate to the intima, resulting in medial and/or intimal calcification. Medial calcific-
ation is typically associated with diabetes [11], and until recently was thought to be related to the ageing process. It
is now seen as a consequence of the smouldering inflammatory storm in patients with this condition, as in others
such as CKD. It may also be due to the presence of promoting factors. Such factors may be present in the proximity
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of vascular cells and/or in the circulation, raising the possibility that sera from such settings may have the potential
to induce VC outside the disease milieu. In this regard, we have previously reported on the in vitro CP of sera from
CKD patients and further demonstrated this increases with declining renal function [8]. In the present study, we have
extended these investigations and compared the CP of serum from controls and from two cohorts of patients with
diabetes, those with and without in vivo VC to establish whether (i) serum from subjects with diabetes has in vitro
CP and (ii) the in vitro CP correlates with the presence of VC in vivo. Both groups of subjects with diabetes had
preserved renal function. The CP of sera from these two groups was compared with that of age- and sex-matched
controls with no evidence of diabetes, CKD or any other major illness.
In vivo VCwas detected in some patients with diabetes and, interestingly, in some subjects in the control group. The
degree of VC in diabetes subjects was significantly higher than in controls, confirming that the presence of diabetes
provides a favourable milieu for VC [1,12]. There was no significant difference in VC induced by serum from subjects
with diabetes who were taking insulin compared with those not on this therapy, suggesting that the latter did not
influence VC in our model. It is, however, worth noting that insulin has been reported to accelerate calcification but
only at high doses [13]. We did not investigate the effects of insulin nor underlying mechanisms such as altered nitric
oxide which may be involved in mediating its effects on calcification.
In both controls and diabetes groups, in vivo VC correlated with age and with OPG. There was also a trend for
diabetics with VC to have lower diastolic pressures and increased pulse pressures, most likely a consequence of VC
[14]. Renal function was identical across the groups though, unsurprisingly, the degree of microalbuminuria was
greater in subjects with diabetes. Levels of CRP were similar between groups suggesting that inflammation may not
be the main driver for calcification in this setting. Similarly, there were no differences in serum levels of calcium,
phosphate and PTH. Serum OPG levels were elevated in the C+ and T2DM+ but not in the C− or T2DM−
groups and this may be a factor in the increased CP of serum from these subjects. Serum MGP levels were slightly
lower in controls with VC, and though higher in subjects with diabetes, they were not influenced by the presence
of VC in this setting. Lipid profiles were generally better in patients with diabetes, probably because more of these
subjects were taking lipid-lowering therapies.
The results obtained from our present studies have highlighted an interesting and novel property of serum from
diabetes which has higher CP than controls. This is consistent with our initial observations on CKD sera [8]. It is also
consistent with one other study demonstrating that culture of vascular smooth muscle cells in serum from subjects
with diabetes and Charcot neuroarthropathy caused accelerated osteoblastic differentiation and mineralization in-
dicative of VC [15]. These similarities in research findings suggest that CP is inherent in serum from disease settings
associated with in vivo VC and highlight the value of cultured vascular smooth muscle cells as a model for the study
of in vitro VC.
In addition to the findings reported above, we have also demonstrated that CP along with age is an independent
predictor of the presence of VC. Moreover, 100 nmoles of Ca2+ protein mg− 1 present in serum predict VC with
a high specificity though with only moderate sensitivity. The CP determined exhibited bimodal distribution with a
higher proportion of sera from subjects with in vivo calcification, particularly those with diabetes, falling within the
higher CP group where Ca2+ levels were above the cutoff value of 100 nmoles of Ca2+ protein mg− 1. Furthermore,
levels of OPG and MGP within the high CP group were significantly higher than those with lower CP and appear
predictive of the CP of serum. Thus, taken together, our data suggest that the CP of serummay be determined by the
presence of diabetes, in vivo calcification and elevated OPG and MGP levels.
The CP of serum from subjects with diabetes and VC (T2DM+ ) was significantly greater than that in controls
(C− and C+ ) and greater, though not significantly so, than that of T2DM− serum. These observations support
the notion that the presence of diabetes confers CP on serum which is further enhanced in the presence of in vivo
calcification. In controls, CP was higher in C+ than in C− but not significantly so. This is likely to be an effect of
small sample size. There was also a significant age difference between the C+ and C− groups suggesting that age
may contribute to the enhanced CP of serum from control subjects with in vivo calcification.
The underlying cellular mechanisms which may mediate CP have not been examined in detail. However, the
changes we observed in OPG andMGP levels may be relevant since, along with RANKL, they are reported to regulate
VC. Increased levels of serum OPG have been found in subjects with renal disease and diabetes and correlated with
arterial stiffness [16–18]. Levels of OPG have also been reported to be elevated at sites of calcification within vessels,
suggesting a role in the process [19]. Furthermore, Moreno et al. [16] demonstrated that a 1 pmol·l− 1 elevation in
OPG serum level amplified the risk of increased intimalmedial thickness by 1.84, aortic calcification by 2.21 and peri-
pheral artery disease by 4.02. These observations imply a critical role for OPG in the development of VC. Consistent
with this are our observations that OPG levels were significantly higher in both the T2DM+ and C+ groups than
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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their counterparts without VC (Table 2), and higher too in sera in the higher strata of the CP distribution (Figure 3).
Elevated OPG expression may thus be a factor contributing to the higher CP of the serum.
Other mediators such as MGP present in sera from subjects with diabetes may also have a role. MGP exists in
serum in the carboxylated (active) and/or uncarboxylated (inactive) form [20]. Carboxylated MGP inhibits the de-
velopment of VC by negating the seeding of calcium phosphate crystals and inhibiting bone morphogenetic proteins
[21], whilst uncarboxylated MGP may promote calcification. The ratio of uncarboxylated/carboxylated MGP levels
and the expression of the γ -carboxylase enzyme have been correlated with medial artery calcification, aortic sten-
osis [22] and cardiovascular events [23]. Furthermore, reduced γ -carboxylation of MGP has been described in the
context of the systemic inflammatory state associated with diabetes which would tend to enhance the concentration
of uncarboxylated MGP [24], thus promoting VC in subjects with diabetes. We measured total MGP, but the higher
CP of sera from subjects with diabetes might suggest a predominance of the uncarboxylated form. Further work is
necessary in this area.
To determine whether CP could be potentiated within a calcifying environment, additional studies were carried
out in which cells were incubated with serum in the presence of a CB as previously described using predetermined
concentrations of CaCl2 and β-GP which induced VC but did not affect cell viability [8]. In the present studies, the
CB did not cause any marked changes in the CP of control sera but significantly enhanced that from subjects with
diabetes, particularly those without pre-existing VC. It is likely that serum from the latter group had already been
primed in vivo and could, therefore, caused enhanced calcification under favourable conditions which promote the
process even in vitro. In contrast, the limited increase in calcification seen with serum from the T2DM+ groupmay
reflect a saturation effect of the potential to promote calcification in the presence of pre-existing calcification.What is
important, however, is that sera from diabetes subjects exhibit enhanced CP which can be further augmented within
a calcifying environment. The priming of the serum in vivo may be a consequence of changes in levels of promoters
and/or inhibitors of calcification. This remains to be investigated.
Our study has some limitations. Firstly, the number of subjects was relatively small and may need to be increased
in future studies to confirm significance, especially where these have been shown to be marginal. Secondly, the
cross-sectional nature of the study precludes observations on the time course and in particular whether the CP of
sera changes with disease progression and treatment. This is important given the potential use of in vitro and in vivo
correlates of CP to estimate an individual’s risk of calcification and to monitor the effects of therapy. Further work is
necessary in this area and also on the mechanisms underlying these observations. This will allow us to infer whether
the associations of OPG and MGP levels with diabetes and calcification are causal or just related to disease progres-
sion. Finally, our studies focused on Caucasians but a multi-ethnic study of atherosclerosis (MESA) has shown that
Caucasians have the highest risk score for calcification followed by Chinese, Hispanics and African Americans [25].
We know of no studies that have compared the CP of serum in different ethnic groups. This will be addressed in our
future studies.
In summary, using our model of VC, we have demonstrated that serum from subjects with diabetes possesses
in vitro CP greater than that of controls and which is related to the degree of in vivo femoral artery calcification
evident on CT scanning. That some patients with diabetes do not develop VCmay provide an important mechanistic
window to address in future studies. Future developments may allow the identification of biomarker profiles which
may be useful in predicting risks of calcification in subjects with diabetes through a blood test rather than the use of
expensive imaging techniques. In addition, itmay also aid inmonitoring responses to therapy, in exploring underlying
mechanisms and in identifying potential novel therapeutic strategies for managing patients at risk.
Clinical perspectives
• Studies were conducted to investigate whether diabetes confers a calcific potential (CP) to serum,
enabling the latter to induce vascular calcification (VC). Should this be the case, serum could be
exploited to develop diagnostic and prognostic tests to determine an individual’s risk of developing
VC and inform therapeutic strategies.
• Serum from T2DM showed significantly greater CP than controls and correlated well with the pres-
ence of VC in vivo. The CP determined exhibited bimodal distribution with a higher proportion of
sera from T2DM subjects with in vivo calcification. The T2DM group also showed elevated levels of
osteoprotegerin and matrix Gla protein.
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• Diabetes conferred CP to serum which, along with age, was an independent predictor of the pres-
ence of in vivo VC. The findings could be exploited for early identification of individuals at risk of VC
and may lead to the design of effective therapeutic strategies to intervene with this process.
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